Skip to main content
Premium Trial:

Request an Annual Quote

Changes Come to Genzyme

Henri Termeer, the CEO of Genzyme, told the Wall Street Journal's Health Blog last week that he was considering selling some of the company's non-essential business, and this week the company said which ones were for sale: its genetic testing, diagnostics, and pharmaceutical intermediates businesses. "As we evaluated our company to create a mix of businesses that will deliver sustainable growth and stronger returns on invested capital, it became clear that these businesses do not fit within this strategy," Termeer says in a statement, according to Dow Jones Newswires. The Health Blog adds that when it "chatted with Termeer last week, he was full of praise from one of the activist investors who's been pressing for change at the company — Ralph Whitworth" though Termeer "had fewer kind words for Carl Icahn."

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.